NFL BIOSCIENCES: CLINICAL TRIAL APPROVED TO DEMONSTRATE THE COMPLEMENTARITY OF NFL-101 WITH OTHER SMOKING CESSATION TREATMENTS
08 nov. 2022 12h00 HE
|
NFL BIOSCIENCES
NFL BIOSCIENCES: CLINICAL TRIAL APPROVED TO DEMONSTRATE THE COMPLEMENTARITY OF NFL-101 WITH OTHER SMOKING CESSATION TREATMENTS NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a...
NFL BIOSCIENCES : AUTORISATION D’ESSAI CLINIQUE POUR DÉMONTRER LA COMPLÉMENTARITÉ DE NFL-101 AVEC LES AUTRES TRAITEMENTS DE SEVRAGE TABAGIQUE
08 nov. 2022 12h00 HE
|
NFL BIOSCIENCES
NFL BIOSCIENCES : AUTORISATION D’ESSAI CLINIQUE POUR DÉMONTRER LA COMPLÉMENTARITÉ DE NFL-101 AVEC LES AUTRES TRAITEMENTS DE SEVRAGE TABAGIQUE NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 –...
NFL BIOSCIENCES: NEW PATENT APPLICATION ASSOCIATING NFL-101 WITH OTHER SMOKING CESSATION TREATMENTS
02 nov. 2022 03h00 HE
|
NFL BIOSCIENCES
NFL BIOSCIENCES: NEW PATENT APPLICATION ASSOCIATING NFL-101 WITH OTHER SMOKING CESSATION TREATMENTS NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company...
NFL BIOSCIENCES : NOUVELLE DEMANDE DE BREVET ASSOCIANT NFL-101 AUX AUTRES TRAITEMENTS DE SEVRAGE TABAGIQUE
02 nov. 2022 03h00 HE
|
NFL BIOSCIENCES
NFL BIOSCIENCES : NOUVELLE DEMANDE DE BREVET ASSOCIANT NFL-101 AUX AUTRES TRAITEMENTS DE SEVRAGE TABAGIQUE NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), société biopharmaceutique...
NFL Biosciences: 2022 first-half business and earnings
25 oct. 2022 01h00 HE
|
NFL BIOSCIENCES
NFL Biosciences: 2022 first-half business and earnings Phase II/III clinical trial for the drug candidate NFL-101 for smoking cessation continues to move forward, with the participation of eight...
NFL Biosciences : Activités & Résultats du 1er semestre 2022
25 oct. 2022 01h00 HE
|
NFL BIOSCIENCES
NFL Biosciences : Activités & Résultats du 1er semestre 2022 L’étude clinique de Phase II/III du candidat médicament NFL-101 pour le sevrage tabagique se poursuit avec la participation de 8...
NFL BIOSCIENCES PARTNERS WITH THEMIS MEDICARE FOR THE DEVELOPMENT OF NFL-101 IN INDIA
05 oct. 2022 12h45 HE
|
NFL BIOSCIENCES
NFL BIOSCIENCES PARTNERS WITH THEMIS MEDICARE FOR THE DEVELOPMENT OF NFL-101 IN INDIA NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical...
NFL BIOSCIENCES CONCLUT UN PARTENARIAT AVEC THEMIS MEDICARE POUR LE DÉVELOPPEMENT DE NFL-101 EN INDE
05 oct. 2022 12h45 HE
|
NFL BIOSCIENCES
NFL BIOSCIENCES CONCLUT UN PARTENARIAT AVEC THEMIS MEDICARE POUR LE DÉVELOPPEMENT DE NFL-101 EN INDE NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), société biopharmaceutique...
NFL BIOSCIENCES HALF-YEAR REVIEW OF THE LIQUIDITY AGREEMENT FOR H1 2022
26 juil. 2022 11h45 HE
|
NFL BIOSCIENCES
NFL BIOSCIENCESHALF-YEAR REVIEW OF THE LIQUIDITY AGREEMENT FOR H1 2022 Under the liquidity agreement concerning NFL Biosciences SA shares (FR0014003XT0 - ALNFL), entrusted to Invest Securities, the...
NFL BIOSCIENCES BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE S1 2022
26 juil. 2022 11h45 HE
|
NFL BIOSCIENCES
NFL BIOSCIENCESBILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE S1 2022 Au titre du contrat de liquidité portant sur les actions de la société NFL Biosciences SA (FR0014003XT0 - ALNFL) confié à Invest...